Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - furosemide, quantity: 20 mg - tablet - excipient ingredients: magnesium stearate; sodium starch glycollate type a; pregelatinised maize starch; maize starch; lactose monohydrate - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - furosemide, quantity: 40 mg - tablet - excipient ingredients: sodium starch glycollate type a; maize starch; lactose monohydrate; magnesium stearate; pregelatinised maize starch - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - gabapentin, quantity: 400 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide; iron oxide red; iron oxide yellow - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - gabapentin, quantity: 300 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide; iron oxide yellow - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - gabapentin, quantity: 100 mg - capsule - excipient ingredients: lactose monohydrate; maize starch; purified talc; gelatin; purified water; sodium lauryl sulfate; titanium dioxide - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs. gabapentin is indicated for the treatment of neuropathic pain.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; hypromellose; polysorbate 80; pregelatinised maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amitriptyline hydrochloride, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; macrogol 6000; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; crospovidone; titanium dioxide; maize starch; purified talc; sunset yellow fcf aluminium lake; hypromellose; indigo carmine aluminium lake - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amitriptyline hydrochloride, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; brilliant blue fcf aluminium lake; titanium dioxide; macrogol 6000; magnesium stearate; purified talc; hypromellose; maize starch; crospovidone - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.